Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
Moderna CEO Stephane Bancel sees his company’s product mix three years from now being 50% infectious diseases, 30% oncology, and 20% rare illnesses by revenue, virtually unchanged from what he envisioned two years ago despite its R&D retrenchment. Bancel shared…
To read the full story
Related Article
- Moderna Japan Looks Beyond COVID for Next Growth Pillars
June 9, 2026
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
July 22, 2025
- Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
- Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
BUSINESS
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Chugai Files Enspryng for MOGAD Relapse Prevention in Japan
August 3, 2026
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…